What question did this study set out to answer?

This study aims to evaluate the effectiveness, safety, and biomarker correlations of trastuzumab biosimilar CT-P6 combined with pertuzumab in neoadjuvant treatment for HER2-positive early breast cancer.

January 22, 2026Breast Cancer Research and TreatmentOpen Access

Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the effectiveness, safety, and biomarker correlations of trastuzumab biosimilar CT-P6 combined with pertuzumab in neoadjuvant treatment for HER2-positive early breast cancer.
Prospective, multicenter, observational study.
Involvement of 102 patients with HER2-positive early breast cancer.
Patients received various neoadjuvant regimens with or without anthracyclines.
Primary endpoint was pathologic complete response (pCR).
Biomarker analyses included soluble HER2 and anti-trastuzumab CT-P6 antibodies.
Pathologic complete response (pCR) achieved in 57.43% of patients undergoing surgery.
No significant difference in pCR between patients on anthracycline and non-anthracycline regimens.
Grade 3–4 adverse events included diarrhea (2.25%) and asthenia (0.50%).
No evidence of immunogenicity or clinically significant cardiotoxicity was observed.

Authors

JAJosé Luis Alonso-RomeroGarrahan Hospital JMJerónimo Martínez-GarcíaInstituto Murciano de Investigación Biosanitaria RCRaúl Carrillo-VicenteSanta Lucía University General Hospital

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational study evaluates pCR in HER2-positive early breast cancer with CT-P6 and pertuzumab, suggesting effective treatment options.

Cite This Study

Alonso-Romero et al. (2026) studied this question.

synapsesocial.com/papers/6971bea8642b1836717e35df https://doi.org/10.1007/s10549-026-07895-8

View Full Paper

Ask AI

Bookmark

Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer

Key Points

Discussion

Implication

Cite This Study

Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider